These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28159831)

  • 1. Prion-Like Protein Aggregates and Type 2 Diabetes.
    Mukherjee A; Soto C
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2 diabetes as a protein misfolding disease.
    Mukherjee A; Morales-Scheihing D; Butler PC; Soto C
    Trends Mol Med; 2015 Jul; 21(7):439-49. PubMed ID: 25998900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism.
    Mukherjee A; Morales-Scheihing D; Salvadores N; Moreno-Gonzalez I; Gonzalez C; Taylor-Presse K; Mendez N; Shahnawaz M; Gaber AO; Sabek OM; Fraga DW; Soto C
    J Exp Med; 2017 Sep; 214(9):2591-2610. PubMed ID: 28765400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
    Moreno-Gonzalez I; Soto C
    Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding.
    Moreno-Gonzalez I; Edwards Iii G; Salvadores N; Shahnawaz M; Diaz-Espinoza R; Soto C
    Mol Psychiatry; 2017 Sep; 22(9):1327-1334. PubMed ID: 28044060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Amylin Turnover, Misfolding and Toxicity in the Pancreas.
    Bhowmick DC; Kudaibergenova Z; Burnett L; Jeremic AM
    Molecules; 2022 Feb; 27(3):. PubMed ID: 35164285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion-like features of misfolded Aβ and tau aggregates.
    Morales R; Callegari K; Soto C
    Virus Res; 2015 Sep; 207():106-12. PubMed ID: 25575736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of protein misfolding and aggregation by natural phenolic compounds.
    Dhouafli Z; Cuanalo-Contreras K; Hayouni EA; Mays CE; Soto C; Moreno-Gonzalez I
    Cell Mol Life Sci; 2018 Oct; 75(19):3521-3538. PubMed ID: 30030591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice.
    Aitken JF; Loomes KM; Riba-Garcia I; Unwin RD; Prijic G; Phillips AS; Phillips ARJ; Wu D; Poppitt SD; Ding K; Barran PE; Dowsey AW; Cooper GJS
    Biochem Biophys Res Commun; 2017 Jan; 482(4):625-631. PubMed ID: 27865831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human islet amyloid polypeptide in protein misfolding disorders: Mechanisms of aggregation and interaction with biomembranes.
    Saghir AE; Farrugia G; Vassallo N
    Chem Phys Lipids; 2021 Jan; 234():105010. PubMed ID: 33227292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice.
    Mucibabic M; Steneberg P; Lidh E; Straseviciene J; Ziolkowska A; Dahl U; Lindahl E; Edlund H
    Sci Rep; 2020 Nov; 10(1):20438. PubMed ID: 33235246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prions and the potential transmissibility of protein misfolding diseases.
    Kraus A; Groveman BR; Caughey B
    Annu Rev Microbiol; 2013; 67():543-64. PubMed ID: 23808331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
    Costanzo M; Zurzolo C
    Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome.
    Masters SL; O'Neill LA
    Trends Mol Med; 2011 May; 17(5):276-82. PubMed ID: 21376667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models for prion-like diseases.
    Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
    Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Biology of Prions and Prionoids: A Status Report.
    Aguzzi A; Lakkaraju AKK
    Trends Cell Biol; 2016 Jan; 26(1):40-51. PubMed ID: 26455408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.